3144692-98-5
Chemical Structure
CYP51-IN-35
- CAS. Nr.: 3144692-98-5
- Formula:C29H25F2N5O2
- Molecular Weight:513.54
InChIKey: HONXREMABQTYFF-UHFFFAOYSA-N
SMILES: CC(C1=CC=C(C#CC2=CC3=C(CN(CC(O)(C4=CC=C(F)C=C4F)CN5N=NN=C5)CC3)C=C2)C=C1)=O
Biological Activity: CYP51-IN-35 is an orally active CYP51 (lanosterol 14α-demethylase) inhibitor. CYP51-IN-35 acts by blocking Ergosterol (HY-N0181) biosynthesis and the accumulation of 14α-methylsterol, shows weak inhibition of human CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and exhibits human liver microsomal and plasma stability. CYP51-IN-35 dose-dependently inhibits Candida albicans biofilm formation and the yeast-to-hypha transition, demonstrates in vivo antifungal (fungal) efficacy in a mouse infection model, and can be used for research on invasive candidiasis and Candida infections[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CYP51-IN-35 | CYP51-IN-35 is an orally active CYP51 (lanosterol 14α-demethylase) inhibitor. CYP51-IN-35 acts by blocking Ergosterol (HY-N0181) biosynthesis and the accumulation of 14α-methylsterol, shows weak inhibition of human CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and exhibits human liver microsomal and plasma stability. CYP51-IN-35 dose-dependently inhibits Candida albicans biofilm formation and the yeast-to-hypha transition, demonstrates in vivo antifungal (fungal) efficacy in a mouse infection model, and can be used for research on invasive candidiasis and Candida infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
